The Food and Drug Administration Modernization Act is working just as Congress intended for the benefit of patients, according to Tim Franson of Indianapolis-based Lilly Research Laboratories, who testified in front of the House Energy and Commerce Subcommittee on Health on behalf of the Washington-based Pharmaceutical Research and Manufacturers of America.
The Food and Drug Administration Modernization Act is working just as Congress intended for the benefit of patients, according to Tim Franson of Indianapolis-based Lilly Research Laboratories, who testified in front of the House Energy and Commerce Subcommittee on Health on behalf of the Washington-based Pharmaceutical Research and Manufacturers of America.
"The 1997 law has promoted increasingly efficient and effective working relationships between FDA and patients, doctors and regulated industries ⦠and - most significantly and importantly - speedier access for patients to safer and more effective new products and to experimental medicines still in clinical testing," said Franson.
In particular, Franson praised a program established by the FDAMA to encourage research on medicines for children.
"Prior to enactment of FDAMA, FDA and pediatricians had attempted several times to spur the development of drugs for pediatric patients and to increase the labeling on products used for children by encouraging more pediatric studies to be conducted," Franson testified. "Notwithstanding these efforts, many medicines continued to be used for children without adequate labeling information for pediatricians and parents. The pediatric provisions of FDAMA have dramatically improved that situation." According to Franson, 411 studies, funded by pharmaceutical companies, on the use of medicines in children have been generated by the law.
Franson urged the committee to reauthor-ize the pediatric provision, known as the Better Pharmaceuticals for Children Act, which will expire in January 2002. He also urged the renewal of the Prescription Drug User Fee Act in 2002.
"PDUFA has provided FDA with the necessary funds to hire additional reviewers, update the agency's information technology infrastructure and act in a more timely and predictable manner on drug applications," testified Franson. PR
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Unlocking value and cost savings in patient services with technology and talent
October 2nd 2024Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.